Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb;33(2):e4892.
doi: 10.1002/pro.4892.

PBITV3 : A robust and comprehensive tool for screening pathogenic proteomes for drug targets and prioritizing vaccine candidates

Shuvechha Chakraborty  1 , Mehdi Askari  2 , Ram Shankar Barai  3 , Susan Idicula-Thomas  1
Affiliations

PBITV3 : A robust and comprehensive tool for screening pathogenic proteomes for drug targets and prioritizing vaccine candidates

Shuvechha Chakraborty et al. Protein Sci. 2024 Feb.

Abstract

Rise of life-threatening superbugs, pandemics and epidemics warrants the need for cost-effective and novel pharmacological interventions. Availability of publicly available proteomes of pathogens supports development of high-throughput discovery platforms to prioritize potential drug-targets and develop testable hypothesis for pharmacological screening. The pipeline builder for identification of target (PBIT) was developed in 2016 and updated in 2021, with the purpose of accelerating the search for drug-targets by integration of methods like comparative and subtractive genomics, essentiality/virulence and druggability analysis. Since then, it has been used for identification of drugs and vaccine targets, safety profiling of multiepitope vaccines and mRNA vaccine construction against a broad-spectrum of pathogens. This tool has now been updated with functionalities related to systems biology and immuno-informatics and validated by analyzing 48 putative antigens of Mycobacterium tuberculosis documented in literature. PBITv3 available as both online and offline tools will enhance drug discovery against emerging drug-resistant infectious agents. PBITv3 can be freely accessed at http://pbit.bicnirrh.res.in/.

Keywords: antigenicity prediction; drug-target identification; druggability; immune-informatics; prediction algorithm; subtractive genomics; systems biology.

PubMed Disclaimer

Conflict of interest statement

None declared.

Similar articles

See all similar articles

References

    1. Alahari A, Trivelli X, Guérardel Y, Dover LG, Besra GS, Sacchettini JC, et al. Thiacetazone, an antitubercular drug that inhibits cyclopropanation of cell wall mycolic acids in mycobacteria. PLoS One. 2007;2:e1343. - PMC - PubMed
    1. Ammari MG, Gresham CR, Mccarthy FM, Nanduri B. Database update HPIDB 2.0: a curated database for host‐pathogen interactions database update background. Database. 2016;2016:103. - PMC - PubMed
    1. Anis Ahamed N, Panneerselvam A, Arif IA, Syed Abuthakir MH, Jeyam M, Ambikapathy V, et al. Identification of potential drug targets in human pathogen Bacillus cereus and insight for finding inhibitor through subtractive proteome and molecular docking studies. J Infect Public Health. 2021;14:160–168. 10.1016/j.jiph.2020.12.005 - DOI - PubMed
    1. Atron B, Yousif Z. In silico identification of novel therapeutic targets and epitopes among the essential hypothetical protein of pseudomonas aeruginosa: a novel approach for Antivirulence Therapy. Available at Research Square. 2023. 10.21203/rs.3.rs-2679079/v1 - DOI
    1. Bertholet S, Ireton GC, Kahn M, Guderian J, Mohamath R, Stride N, et al. Identification of human T cell antigens for the development of vaccines against mycobacterium tuberculosis. J Immunol. 2008;181:7948–7957. - PMC - PubMed

LinkOut - more resources